Wednesday, 13 Nov 2019

You are here

FDA Reviews the Safety of Lesinurad in Gout

Lesinurad is a novel URAT-1 inhibitor being developed as a urate-lowering therapy for gout by Astra-Zeneca.

The U.S. Food and Drug Administration has raised questions about the safety of this new drug as the application for drug approval is slated for review later this week. Specifically, the FDA has concerns over higher death rates, cardiovascular issues and kidney-related side effects for those taking lesinurad.

The manufacturer has proposed that lesinurad be used in combination with either allopurinol or febuxostat as a more effective means of ULT.

An FDA advisory panel of independent advisers will convene on Friday, October 23, 2015, to assess the safey and efficacy of this new agent. (FDA Briefing Document )

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.